Aurobindo to resume production at aseptic lines of Eugia Pharma's Unit-III
Wednesday, 13 March 2024
Aurobindo Pharma plans to resume commercial production at Eugia Pharma's Pashamylaram formulations facility in Hyderabad. Distribution of aseptic products has restarted. World Health Organisation recommends Unit-IV of its wholly owned subsidiary APL Healthcare as a manufacturing site for Dolutegravir, Lamivudine, Tenofovir Disoproxil Fumarate Tablets. Production to resume by April 15, 2024.
|
||||
|
|
||||
You Might Like |
||||
